## Zhifei Xu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3303493/publications.pdf Version: 2024-02-01



7<u>hiffi Xii</u>

#	Article	IF	CITATIONS
1	<p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy</p> . Drug Design, Development and Therapy, 2020, Volume 14, 3625-3649.	2.0	80
2	Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 767-774.	1.5	58
3	High-mobility group box 1 protein-mediated necroptosis contributes to dasatinib-induced cardiotoxicity. Toxicology Letters, 2018, 296, 39-47.	0.4	37
4	HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport. Autophagy, 2018, 14, 2155-2170.	4.3	34
5	PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1). Autophagy, 2021, 17, 3221-3237.	4.3	33
6	Bisdemethoxycurcumin attenuates cisplatin-induced renal injury through anti-apoptosis, anti-oxidant and anti-inflammatory. European Journal of Pharmacology, 2020, 874, 173026.	1.7	29
7	Regulation of p53 stability as a therapeutic strategy for cancer. Biochemical Pharmacology, 2021, 185, 114407.	2.0	27
8	Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1. British Journal of Cancer, 2017, 116, 1027-1036.	2.9	26
9	s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand–foot skin reaction that can be reversed by nicotinamide. Cell Research, 2020, 30, 779-793.	5.7	24
10	The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome. Environmental Toxicology and Pharmacology, 2017, 49, 81-88.	2.0	22
11	Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair. PLoS ONE, 2016, 11, e0146968.	1.1	21
12	Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib. Autophagy, 2022, 18, 1152-1173.	4.3	16
13	Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies. Expert Review of Clinical Pharmacology, 2021, 14, 445-456.	1.3	13
14	Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 823-835.	1.5	12
15	All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARα-mediated DNA damage. BMC Cancer, 2016, 16, 2.	1.1	8
16	Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1311-1325.	1.5	5
17	Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation. Biomedicine and Pharmacotherapy, 2021, 144, 112297.	2.5	4
18	Decreased HMGB1 expression contributed to cutaneous toxicity caused by lapatinib. Biochemical Pharmacology, 2022, 201, 115105.	2.0	3

#	Article	IF	CITATIONS
19	COVID-19 epidemic: a special focus on diagnosis, complications, and management. Expert Review of Clinical Pharmacology, 2020, 13, 1085-1093.	1.3	2